Literature DB >> 16908336

Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts.

Karin S Coyne1, Andrea Tubaro, Linda Brubaker, Tamara Bavendam.   

Abstract

Patient-reported outcome (PRO) measures are a valuable means for determining how a disease and its treatment affect patients, including effects on health-related quality of life (HRQL). To ensure that the results obtained with PROs are clinically useful, data must be gathered using valid and reliable instruments. Developing such instruments requires a multistep, structured process that incorporates cognitive psychology, psychometric theory, and patient and clinician input. The process begins by determining the intent and purpose of the PRO and culminates in studies that demonstrate the measure's validity, reliability, and responsiveness. Several valid and reliable PROs are available for assessing the effects of treatment on symptom severity, symptom bother, and HRQL in patients with overactive bladder.

Entities:  

Mesh:

Year:  2006        PMID: 16908336     DOI: 10.1016/j.urology.2006.05.042

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  35 in total

Review 1.  Self-report measurement of lower urinary tract symptoms: a commentary on the literature since 2011.

Authors:  James W Griffith
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

2.  Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Authors:  Salvador Arlandis; Miguel A Ruiz; Carlos Errando; Felipe Villacampa; Daniel Arumí; Isabel Lizarraga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

Review 3.  Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials.

Authors:  Joseph M Unger; Riha Vaidya; John L Gore
Journal:  Urol Oncol       Date:  2018-03-21       Impact factor: 3.498

4.  Clinical validation of the Bladder Health Survey for urinary incontinence in a population sample of women.

Authors:  Vatché A Minassian; Xiaowei S Yan; Haiyan Sun; Raissa O Platte; Walter F Stewart
Journal:  Int Urogynecol J       Date:  2015-09-19       Impact factor: 2.894

5.  Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms.

Authors:  Seong Jin Jeong; Yukio Homma; Seung-June Oh
Journal:  Qual Life Res       Date:  2013-05-29       Impact factor: 4.147

6.  Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.

Authors:  Rebecca Rogers; Gloria Bachmann; Zhanna Jumadilova; Franklin Sun; Jon D Morrow; Zhonghong Guan; Tamara Bavendam
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-08-07

7.  Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation.

Authors:  Giovanni Palleschi; Antonio Luigi Pastore; Cristina Maggioni; Andrea Fuschi; Luca Pacini; Vincenzo Petrozza; Antonio Carbone
Journal:  World J Urol       Date:  2013-10-08       Impact factor: 4.226

8.  Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).

Authors:  V Hagelstein; I Ortland; A Wilmer; S A Mitchell; U Jaehde
Journal:  Ann Oncol       Date:  2016-09-28       Impact factor: 32.976

9.  Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire.

Authors:  Sieta T de Vries; Peter G M Mol; Dick de Zeeuw; Flora M Haaijer-Ruskamp; Petra Denig
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

10.  Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.

Authors:  J J Wyndaele; E R Goldfischer; J D Morrow; J Gong; L J Tseng; Z Guan; M S Choo
Journal:  Int J Clin Pract       Date:  2009-04       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.